IMUC has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
IMUC has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
The historical data trend for EOM Pharmaceutical Holdings's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EOM Pharmaceutical Holdings Annual Data | |||||||||||||||||||||
Trend | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | |||||||||||
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
EOM Pharmaceutical Holdings Quarterly Data | ||||||||||||||||||||
Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | |
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, EOM Pharmaceutical Holdings's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where EOM Pharmaceutical Holdings's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
EOM Pharmaceutical Holdings's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2018 is calculated as:
For example, EOM Pharmaceutical Holdings's adjusted Book Value per Share data for the three months ended in Jun. 2018 was:
Adj_Book | = | Book Value per Share | / | CPI of Jun. 2018 (Change) | * | Current CPI (Jun. 2018) |
= | 0.818 | / | 106.3168 | * | 106.3168 | |
= | 0.818 |
Current CPI (Jun. 2018) = 106.3168.
EOM Pharmaceutical Holdings Quarterly Data
Book Value per Share | CPI | Adj_Book | |
200809 | 110.943 | 92.307 | 127.781 |
200812 | 92.715 | 88.697 | 111.132 |
200903 | 76.254 | 89.744 | 90.335 |
200906 | 58.313 | 91.003 | 68.126 |
200909 | 49.864 | 91.120 | 58.180 |
200912 | 29.513 | 91.111 | 34.438 |
201003 | 44.725 | 91.821 | 51.786 |
201006 | 88.122 | 91.962 | 101.878 |
201009 | 69.384 | 92.162 | 80.041 |
201012 | 42.067 | 92.474 | 48.364 |
201103 | 68.912 | 94.283 | 77.707 |
201106 | 54.457 | 95.235 | 60.794 |
201109 | 62.866 | 95.727 | 69.821 |
201112 | 45.184 | 95.213 | 50.453 |
201203 | 66.524 | 96.783 | 73.077 |
201206 | 23.201 | 96.819 | 25.477 |
201209 | 29.442 | 97.633 | 32.061 |
201212 | 179.169 | 96.871 | 196.639 |
201303 | 142.654 | 98.209 | 154.430 |
201306 | 170.832 | 98.518 | 184.356 |
201309 | 177.882 | 98.790 | 191.435 |
201312 | 184.026 | 98.326 | 198.982 |
201403 | 163.269 | 99.695 | 174.114 |
201406 | 163.772 | 100.560 | 173.148 |
201409 | 153.962 | 100.428 | 162.990 |
201412 | 146.481 | 99.070 | 157.196 |
201503 | 143.454 | 99.621 | 153.096 |
201506 | 130.469 | 100.684 | 137.768 |
201509 | 116.441 | 100.392 | 123.314 |
201512 | 96.200 | 99.792 | 102.490 |
201603 | 72.083 | 100.470 | 76.278 |
201606 | 50.884 | 101.688 | 53.200 |
201609 | 33.763 | 101.861 | 35.240 |
201612 | 17.801 | 101.863 | 18.579 |
201703 | 1.389 | 102.862 | 1.436 |
201706 | -8.270 | 103.349 | -8.507 |
201709 | -0.220 | 104.136 | -0.225 |
201712 | 1.109 | 104.011 | 1.134 |
201803 | 0.876 | 105.290 | 0.885 |
201806 | 0.818 | 106.317 | 0.818 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
EOM Pharmaceutical Holdings (OTCPK:IMUC) Cyclically Adjusted PB Ratio Explanation
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thank you for viewing the detailed overview of EOM Pharmaceutical Holdings's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrew Gengos | director | 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367 |
Gary Titus | director, officer: Chairman and Secretary | SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125 |
Anthony Gregg Lapointe | director | PO BOX 83216, GAITHERSBURG MD 20883-3216 |
Mark A Schlossberg | director | C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544 |
Rahul Singhvi | director | 246 HOLLY DRIVE, CHALFONT PA 18914 |
Helen Susan Kim | director | 3832 BAY CENTER PLACE, HAYWARD CA 94545 |
Richard Chin | director | C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451 |
Richard Cowell | director | 7840 VIRGINIA OAK DRIVE, GAINSVILLE VA 20155 |
James G. Bender | officer: VP, Product Development & Mfg. | 112 WEST 34TH STREET, 17TH FLOOR, NEW YORK NY 10120 |
Manish Singh | director, officer: President & CEO | 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367 |
Jacqueline Brandwynne | director | 649 STONE CANYON ROAD, LOS ANGELES CA 90077 |
From GuruFocus
By PRNewswire PRNewswire • 10-16-2018
By PRNewswire • 11-14-2023
By Marketwired Marketwired • 08-09-2019
By PRNewswire PRNewswire • 04-12-2018
By PRNewswire PRNewswire • 03-26-2018
By PRNewswire PRNewswire • 10-17-2019
By PRNewswire PRNewswire • 06-28-2021
By PRNewswire PRNewswire • 07-16-2019
By PRNewswire PRNewswire • 12-02-2021
By PRNewswire PRNewswire • 03-14-2018
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.